BriaCell Phase 3 metastatic breast cancer trial adds Memorial Sloan Kettering site

• BriaCell added Memorial Sloan Kettering Cancer Center as an enrolling site for its pivotal Phase 3 metastatic breast cancer trial.
• Trial evaluates Bria-IMT with an immune checkpoint inhibitor versus physician’s choice, targeting heavily pretreated patients with limited options.
• Overall survival is the primary endpoint, with an interim look planned once enough deaths occur to support a comparison.
• No new efficacy results were presented; prior Phase 2 survival findings were previously disclosed, including at ASCO 2026.
• Expansion lifts the study to more than 80 active sites across 15 states, broadening recruitment for a program with FDA Fast Track status.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080730PRIMZONEFULLFEED9821867) on September 08, 2026, and is solely responsible for the information contained therein.